• EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

    Source: Nasdaq GlobeNewswire / 02 Nov 2022 07:00:00   America/Chicago

    Company to host conference call and webcast on Thursday, November 17th at 8:30 am EDT

    LYON, France, November 2, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th after the markets close on Wednesday, November 16th, 2022.

    An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 17th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

    Conference Call & Webcast
    Thursday, November 17th @ 8:30am Eastern Time
    Domestic:        877-451-6152
    International:   201-389-0879
    Passcode:        13733576
    Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1576059&tp_key=6f7ca662d1

    About EDAP TMS SA

    A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.

    Company contact:
    Blandine Confort
    Investor Relations / Legal Affairs
    EDAP TMS SA
    +33 4 72 15 31 50
    bconfort@edap-tms.com

    Investor Contact
    John Fraunces
    LifeSci Advisors, LLC
    212-915-2568
    jfraunces@lifesciadvisors.com


    Primary Logo

Share on,